Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Ardelyx inc org - The Untold Story

Healthcare Innovation: 3 Biotech Stocks to Watch in May 2023

As the biotech sector is expanding rapidly in response to the growing need for healthcare solutions, fundamentally strong biotech stocks Amicus Therapeutics (FOLD), Ardelyx (ARDX), and Genfit S.A. (GNFT) have the potential to generate substantial returns for investors. Hence, these stocks could be solid watchlist additions this month. Read more….

StockNews.com · May 4, 2023

Why Ardelyx Shares Are Rising

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from the OND, CDER and FDA for the company’s second level of appeal of the Complete Response Letter for XPHOZAH.

Benzinga · Apr 25, 2022

FDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis

The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx Inc's (NASDAQ:ARDX) second level of appeal of the Complete Response Letter (CRL) for Xphozah. Ardelyx is seeking approval for Xphozah to control serum phosphorus in adult patients with chronic kidney disease (CKD) on…

Benzinga · Apr 25, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Kyowa Kirin, Ardelyx Amend Tenapanor Pact In Cardiorenal Disorders

Ardelyx Inc (NASDAQ: ARDX) has

Benzinga · Apr 11, 2022

Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock

Ardelyx Inc (NASDAQ:ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that will launch in April and whose commercial…

Benzinga · Mar 2, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.